Results 161 to 170 of about 232,812 (303)

Real‐World Retrospective Analysis of Daratumumab for Relapsed or Refractory Multiple Myeloma in Regional Australia

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective case series evaluated all patients treated with daratumumab between 2018 and 2023 across two regional hospitals in Australia. Fifty‐two patients were included with a median age of 74. Median progression‐free survival (PFS) was 13 months and overall survival (OS) was 27 months, with an overall response rate was 35%.
Benjamin Reardon   +2 more
wiley   +1 more source

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL

open access: yesHemaSphere, 2023
Peihao Zheng   +11 more
doaj   +1 more source

Reduced Pathogen-Specific T Cell Response With BCMA-Targeted T Cell-Engaging Therapy to Multiple Myeloma. [PDF]

open access: yesEJHaem
Steiro I   +9 more
europepmc   +1 more source

Implementation and Management of Cancer Clinical Quality Registries in Australia: A Qualitative Study

open access: yesAsia-Pacific Journal of Clinical Oncology, EarlyView.
While stakeholders saw value in cancer CQRs, concerns about funding, staffing, ethics, governance, and data quality were viewed as threats to sustainability. Ensuring ongoing value and viability will require investments in staff training and recruitment, integration with existing data collections, and clearer uses of CQR data to improve healthcare ...
Ashleigh R. Sharman   +2 more
wiley   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

open access: yesAllergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller   +16 more
wiley   +1 more source

Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients

open access: yesBlood Cancer Journal
Hira Cheema   +13 more
doaj   +1 more source

Understanding the Type 2 Immunity: An Evolving View Beyond Allergic Diseases

open access: yesAllergy, EarlyView.
ABSTRACT Type 2 (T2) immunity is classically associated with defense against helminths and environmental threats, from a physiological perspective, and with allergies and eosinophilic inflammatory diseases, in a pathological sense. However, growing evidence reveals that T2 pathways also support other essential homeostatic functions, including tissue ...
Rodrigo Jiménez‐Saiz   +22 more
wiley   +1 more source

Factors Affecting Prognosis in Patients with Extramedullary Myeloma: A Single-Center Experience. [PDF]

open access: yesJ Clin Med
Bozan E   +11 more
europepmc   +1 more source

Multiple myeloma [PDF]

open access: yesClinical Medicine, 2001
D, Samson, C, Singer
openaire   +2 more sources

Home - About - Disclaimer - Privacy